Jiangsu Gdk Biological Technology Co., Ltd (SHA:688670)
China · Delayed Price · Currency is CNY 17.94
+0.21 (1.18%)
Apr 30, 2026, 2:14 PM CST
SHA:688670 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 110.32 | 112.88 | 80.8 | 134.59 | 318.49 | 390.56 |
Other Revenue | - | - | - | - | - | 1.71 |
| 110.32 | 112.88 | 80.8 | 134.59 | 318.49 | 392.27 | |
Revenue Growth (YoY) | 39.20% | 39.70% | -39.96% | -57.74% | -18.81% | -33.41% |
Cost of Revenue | 41.69 | 40.22 | 51.87 | 86.29 | 87.41 | 114.52 |
Gross Profit | 68.63 | 72.67 | 28.93 | 48.3 | 231.07 | 277.75 |
Selling, General & Admin | 144.48 | 148.96 | 117.06 | 134.1 | 166.35 | 163.09 |
Research & Development | 91.83 | 91.78 | 33.61 | 15.47 | 32.41 | 35.26 |
Other Operating Expenses | 1.63 | 1.65 | 1.93 | 1.35 | 2.84 | 3.56 |
Operating Expenses | 237.95 | 242.39 | 155.27 | 139.66 | 202.75 | 203.18 |
Operating Income | -169.32 | -169.72 | -126.34 | -91.36 | 28.32 | 74.58 |
Interest Expense | - | - | -1.6 | -1.9 | -1.28 | -9.85 |
Interest & Investment Income | 5.17 | 6.42 | 13.04 | 15.15 | 17.53 | 7.69 |
Currency Exchange Gain (Loss) | - | - | - | - | 0 | - |
Other Non Operating Income (Expenses) | -4.62 | -4.98 | -3.81 | -0.9 | -0.02 | -0.01 |
EBT Excluding Unusual Items | -168.77 | -168.29 | -118.71 | -79.01 | 44.55 | 72.4 |
Gain (Loss) on Sale of Investments | -0.15 | -0.39 | 0.17 | -0.15 | -1.74 | 2.31 |
Gain (Loss) on Sale of Assets | 0 | 0 | -0.1 | - | 0.23 | -0.05 |
Asset Writedown | -28.51 | -28.53 | -0.88 | -0.24 | -3.29 | -3.75 |
Other Unusual Items | - | - | 3.77 | -7.18 | 8.66 | 13.09 |
Pretax Income | -197.42 | -197.21 | -115.75 | -86.57 | 48.41 | 84 |
Income Tax Expense | -14.15 | -18.75 | -22.25 | -15.58 | 6.86 | 1.54 |
Net Income | -183.27 | -178.46 | -93.5 | -70.99 | 41.54 | 82.46 |
Net Income to Common | -183.27 | -178.46 | -93.5 | -70.99 | 41.54 | 82.46 |
Net Income Growth | - | - | - | - | -49.62% | -46.79% |
Shares Outstanding (Basic) | 123 | 123 | 123 | 122 | 122 | 105 |
Shares Outstanding (Diluted) | 123 | 123 | 123 | 122 | 122 | 105 |
Shares Change (YoY) | -0.12% | 0.04% | 0.52% | 0.17% | 16.43% | 13.67% |
EPS (Basic) | -1.49 | -1.45 | -0.76 | -0.58 | 0.34 | 0.79 |
EPS (Diluted) | -1.49 | -1.45 | -0.76 | -0.58 | 0.34 | 0.79 |
EPS Growth | - | - | - | - | -56.73% | -53.19% |
Free Cash Flow | -203.97 | -201.42 | -169.86 | 26.9 | -129.58 | -282.46 |
Free Cash Flow Per Share | -1.66 | -1.64 | -1.38 | 0.22 | -1.06 | -2.69 |
Dividend Per Share | - | - | - | - | 0.143 | 0.357 |
Dividend Growth | - | - | - | - | -59.98% | - |
Gross Margin | 62.21% | 64.37% | 35.80% | 35.89% | 72.55% | 70.81% |
Operating Margin | -153.48% | -150.35% | -156.35% | -67.88% | 8.89% | 19.01% |
Profit Margin | -166.13% | -158.10% | -115.72% | -52.74% | 13.04% | 21.02% |
Free Cash Flow Margin | -184.90% | -178.43% | -210.22% | 19.99% | -40.69% | -72.01% |
EBITDA | -138.37 | -139.2 | -97.52 | -61.49 | 58.08 | 102.65 |
EBITDA Margin | -125.43% | -123.31% | -120.69% | -45.68% | 18.24% | 26.17% |
D&A For EBITDA | 30.95 | 30.52 | 28.82 | 29.87 | 29.76 | 28.08 |
EBIT | -169.32 | -169.72 | -126.34 | -91.36 | 28.32 | 74.58 |
EBIT Margin | -153.48% | -150.35% | -156.35% | -67.88% | 8.89% | 19.01% |
Effective Tax Rate | - | - | - | - | 14.18% | 1.83% |
Revenue as Reported | - | - | 80.8 | 134.59 | 318.49 | 392.27 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.